mGluR2/3 activation of the SIRT1 axis preserves mitochondrial function in diabetic neuropathy by Chandrasekaran, Krish et al.
RESEARCH ARTICLE
mGluR2/3 activation of the SIRT1 axis preserves mitochondrial
function in diabetic neuropathy
Krish Chandrasekaran1,2 , Anjaneyulu Muragundla1,2, Tyler G. Demarest3, Joungil Choi1,2,
Avinash R. Sagi1, Neda Najimi1, Pranith Kumar1 , Anmol Singh1, Cheng-Ying Ho4, Gary Fiskum3,
Lauren G. Koch5, Steven L. Britton5,6 & James W. Russell1,2,7
1Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland 21201
2Veterans Affairs Medical Center, Baltimore, Maryland 21201
3Department Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland 21201
4Department Pathology, University of Maryland School of Medicine, Baltimore, Maryland 21201
5Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan 48109
6Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan 48109
7Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, Maryland 21201
Correspondence
James W. Russell, Professor, Department of
Neurology, Anatomy and Neurobiology,
University of Maryland School of Medicine,
3S-129, 110 South Paca Street, Baltimore,




Supported in part by the National Institute of
Diabetes and Digestive and Kidney Diseases,
National Institutes of Health 1R01DK107007-
01A1, Office of Research Development,
Department of Veterans Affairs (Biomedical and
Laboratory Research Service and Rehabilitation
Research and Development, 101RX001030), the
American Diabetes Association (ADA), andMid-
Atlantic Nutrition Obesity Research Center, grant
P30 DK072488 from the National Institute of
Diabetes and Digestive and Kidney Diseases,
National Institutes of Health. The LCR-HCR rat
model systemwas funded by the National Center
for Research Resources grant R24 RR017718 and is
currently supported by the Office of Research
Infrastructure Programs/OD grant ROD012098A
(to L.G.K. and S.L.B.) from the National Institutes of
Health. Contact L.G.K. (lgkoch@med.umich.edu)
or S.L.B. (brittons@umich.edu) for information on
the LCR and HCR rats: these rat models are
maintained as an international collaborative
resource by the Department of Anesthesiology at
the University of Michigan, Ann Arbor.
Received: 20 April 2017; Revised: 24 August
2017; Accepted: 30 August 2017
Annals of Clinical and Translational
Neurology 2017; 4(12): 844–858
doi: 10.1002/acn3.484
Abstract
Objectives: There is a critical need to develop effective treatments for diabetic
neuropathy. This study determined if a selective mGluR2/3 receptor agonist
prevented or treated experimental diabetic peripheral neuropathy (DPN)
through glutamate recycling and improved mitochondrial function. Methods:
Adult male streptozotocin treated Sprague-Dawley rats with features of type 1
diabetes mellitus (T1DM) or Low Capacity Running (LCR) rats with insulin
resistance or glucose intolerance were treated with 3 or 10 mg/kg/day
LY379268. Neuropathy end points included mechanical allodynia, nerve con-
duction velocities (NCV), and intraepidermal nerve fiber density (IENFD).
Markers of oxidative stress, antioxidant response, glutamate recycling pathways,
and mitochondrial oxidative phosphorylation (OXPHOS) associated proteins
were measured in dorsal root ganglia (DRG). Results: In diabetic rats, NCV
and IENFD were decreased. Diabetic rats treated with an mGluR2/3 agonist did
not develop neuropathy despite remaining diabetic. Diabetic DRG showed
increased levels of oxidized proteins, decreased levels of glutathione, decreased
levels of mitochondrial DNA (mtDNA) and OXPHOS proteins. In addition,
there was a 20-fold increase in levels of glial fibrillary acidic protein (GFAP)
and the levels of glutamine synthetase and glutamate transporter proteins were
decreased. When treated with a specific mGluR2/3 agonist, levels of glutathione,
GFAP and oxidized proteins were normalized and levels of superoxide dismu-
tase 2 (SOD2), SIRT1, PGC-1a, TFAM, glutamate transporter proteins, and glu-
tamine synthetase were increased in DRG neurons. Interpretation: Activation
of glutamate recycling pathways protects diabetic DRG and this is associated
with activation of the SIRT1-PGC-1a–TFAM axis and preservation of mito-
chondrial OXPHOS function.
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Introduction
There is currently no specific medication that prevents or
reverses diabetic neuropathy in humans. Mitochondria (Mt)
are critical regulators of neuronal survival. Reduced Mt
bioenergetic function and increased oxidative stress are sig-
nificant contributors in diabetic neuropathy.1–7 Key tran-
scription factors, for example, the silent information
regulator protein 1 (SIRT 1) - Peroxisome proliferator-acti-
vated receptor-gamma coactivator 1a (PGC-1a) - mito-
chondrial transcription factor A (TFAM) axis, are critical in
regulating Mt function in response to oxidative stress in
experimental diabetic neuropathy.1,4,8 SIRT1 in neurons is
neuroprotective,9,10 is important in axonal regeneration,11
and deacetylates PGC-1a. The 35-kDa PGC-1a isoform is
critical for reducing oxidative stress and regulation of key
Mt b-oxidation enzymes.4,12,13 The transcription factor acti-
vated by SIRT1- PGC-1a is TFAM, which promotes replica-
tion and transcription of mitochondrial DNA (mtDNA),
wraps Mt DNA to protect it from oxidative stress and
reduces experimental diabetes-induced neuropathy.8,14–16
Oxidative stress, resulting from diabetes, can also result in
di-sulfide bridges in the cysteine residues of the glutamate
transporters causing an inhibition of glutamate flux that
results in elevated levels of extracellular glutamate.17,18
Increased extracellular glutamate, in turn, reverses the cys-
teine/glutamate antiporter, decreases synthesis of glutathione
(GSH or gamma glutamyl-cysteine-glycine), increases
mtDNA damage, and impairs Mt oxidative phosphorylation
systems (OXPHOS).19,20 In contrast, we have previously
shown in cell culture that selective activation of the metabo-
tropic glutamate 2/3 receptor (mGluR2/3) prevents dorsal
root ganglion neuronal (DRG) and Schwann cell oxidative
injury through regulation of oxidative stress pathways and by
maintaining GSH levels.21,22 The neuronal protection occurs
only in the presence of Schwann cells or satellite glial cells
(SGC) that act to mediate glutamate uptake.23–27 Other
mGluRs, for example mGluR5, may result in increased noci-
ceptive transmission in diabetic neuropathic pain.28 How-
ever, it is not known if mGluR2/3 agonists can prevent
experimental diabetic neuropathy, if they result in glutamate
recycling, and how mGluR2/3 agonists affect critical Mt regu-
latory transcription factors such as the SIRT1-PGC-1a-TFAM
axis and components of Mt OXPHOS.
Research design and methods
Experimental animals, diabetes induction
and drug treatment
The animal protocols were reviewed and approved by the
Institutional Animal Care and Use Committee and con-
form to U.S. National Institutes of Health guidelines.
Twelve-week-old male Sprague Dawley (SD) rats (Harlan,
Indianapolis, IN) were injected with intraperitoneal (i.p)
saline or with a single dose of streptozotocin (STZ) at
45 mg/kg and diabetes was confirmed (glucose>300 mg/
dl; =16.7 mmol/L) as previously described.29,30 Animals
were randomly divided into the following groups with
eight animals in each group: (1) nondiabetic control/sal-
ine (2) diabetes (3) diabetes treated with LY 379268
(3 mg/kg) (4) diabetes + LY 379268 (10 mg/kg) (5) non-
diabetic + LY 379268 (3 mg/kg). Daily treatment with
intraperitoneal LY 379268 (Tocris #2453) was started
immediately after animals became diabetic and continued
for 8 weeks. Treated nondiabetic animals received only
3 mg/kg LY 379268 because of the cost and limited avail-
ability of the drug.
Low Capacity Running (LCR) and High Capacity Run-
ning (HCR) rats derived from genetically heterogeneous
N: NIH stock rats by artificial selection for low and high
treadmill running capacity were used as described.12 Aged
male LCR and HCR rats (~12 months old) from genera-
tion 21 of selection were used for this study.31 LCR and
HCR rats were treated either with vehicle (saline) or with
the previously established effective dose of LY379268
(10 mg/kg) for 8 weeks, once the animals had already
developed neuropathy.
Neuropathy measurements
Mechanical allodynia was assessed using Somedic von
Frey monofilaments using the Semmes-Weinstein series
(Somedic Sales AB), sciatic-peroneal and tail nerve con-
duction studies were measured as previously
described.32,33 Briefly, rats were anesthetized with keta-
mine 80–90 mg/kg, and Xylazine 5–10 mg/kg and the
animal was provided with thermal support and warming
lamps. Electrodes were placed adjacent to the nerve to
obtain near nerve recordings using a 60–80 mA square
wave stimulus for 0.1–0.3 msec. NCS were performed in
the tail and left hindlimb using platinum electrodes adja-
cent to the nerve to obtain near nerve recordings. The G1
(active) and G2 (indifferent) recording electrodes were
separated by a distance of 10 mm. Tail NCS were
recorded over a 9 cm distance measured from the base of
the tail. Proximal nerve conduction velocities were mea-
sured over the proximal 5 cm from the base of the tail,
and distal nerve conductions over the terminal 4 cm.
Orthodromic motor conduction velocities were obtained
by recording at the tip of the tail and stimulating with
the cathode 4 and 9 cm proximal to the G1 recording
electrode and subtracting the corresponding latencies.
Orthodromic sensory tail conduction velocities were
obtained by placing G1 at the base of the tail and stimu-
lating 4 and 9 cm distally. Sensory responses were
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averaged until the sensory nerve action potential response
was stable. Distal tail motor and sensory nerve conduc-
tion velocities are reported in the tables. Tail and limb
temperatures were maintained at 32–33°C. The onset
latency and peak amplitude were measured. Mechanical
allodynia was assessed using Somedic von Frey monofila-
ments using the Semmes-Weinstein series (Somedic Sales
AB). Ordinal numbers above 4 were applied gently on the
fat part of the both plantar heels until the hair started to
bend and maintained for approximately 2 sec. The
threshold was defined as the minimal bending force of
the thinnest filament sensed by the rat in an ascending
and descending series of applications. Intraepidermal
nerve fiber density (IENFD) was measured using PGP9.5
antibody staining in a blinded fashion as previously
described.4,33 IENFD was calculated (as fibers/mm) by the
number of complete baseline crossings of nerve fibers at
the dermo-epidermal junction divided by the calculated
length of the epidermal surface.
Tissue collection
At experiment termination, blood was collected; plasma
glycosylated hemoglobin (GHb), insulin, and lipid profiles
were measured. The rats were euthanized and DRG, sci-
atic nerve (SN), and hind paw skin were collected as
described.32,34 We used the whole DRG, which includes
DRG neurons with surrounding satellite cells. Western
blot analysis of proteins was performed as previously
described.4,8,12 L3 to L5 DRG obtained from the experi-
mental groups were processed with a tissue lyser (Qiagen
Inc.). DRG tissues were homogenized in a buffer contain-
ing 50 mmol/L Tris-HCl with 1% Triton X-100 and pro-
tease inhibitors followed by centrifugation at 13,000g.
Protein samples (50 lg) were separated on a 4–20% gra-
dient gel and transferred to PVDF membranes. The mem-
branes were incubated overnight at 4°C. The source and
dilution of the various antibodies used in this study are
shown (Table S1). The membranes were then treated with
the peroxidase-conjugated secondary antibody (Cal-
biochem). Immunostained proteins were detected by
using a SuperSignal chemiluminescence kit (Pierce) and
an Alpha Innotech imaging system. Protein intensity was
normalized to beta actin.
Mitochondrial DNA Quantification
The ratio of mitochondrial DNA (mtDNA to nuclear
DNA (nDNA) was determined by copy number using a
quantitative PCR method.4,12 Genomic DNA was isolated
from the L5 DRG neurons. Mitochondrial DNA copy
number was determined by PCR of two mtDNA targets: a
197-bp ND1 gene and a 199-bp Cyt B gene and the Ct
values were compared with a standard plasmid carrying
ND1 and CytB mtDNA fragments. Nuclear DNA copy
number was determined by PCR for a nuclear DNA 175-
bp B2M gene target and the Ct values were compared
with a plasmid carrying a B2M nuclear gene fragment.
The ratio of mtDNA/nDNA was calculated by 2X (ND1
Copies/20 ng DNA)/(B2M Copies/20 ng DNA); and by 2
X (Cyt B Copies/20 ng DNA)/(B2M Copies/20 ng DNA).
Glutathione measurement
DRG samples were treated with 5% (v/v) sulfosalicylic
acid and centrifuged at 7800g for 10 min to remove dena-
tured proteins, and reduced glutathione (GSH) and oxi-
dized glutathione (GSSG) were determined by an
enzymatic method. The total glutathione (GSH + GSSG)
content was assayed in a cuvette containing 90 lL of the
supernatant in 0.1 mol/L sodium phosphate buffer (pH
7.5), 3 mmol/L 5,50-dithiobis (2-nitrobenzoic acid)
(DTNB) and 0.115 unit/mL glutathione reductase in a
final volume of 1 mL. After 5 min of incubation at room
temperature, 2 mmol/L NADPH was added and the
kinetics of the reaction was monitored for 5 min. The
increment in absorbance at 412 nm was converted to
GSH concentration using a standard curve with known
amounts of GSH.
Statistical analysis
Comparison of dependent variables was performed on
transformed data using factorial analysis of variance
(ANOVA) with post hoc Tukey test to determine the sig-
nificance among the groups and individual comparisons
were made using students T-test, assuming unequal vari-
ances as previously described.32 The associations between
the index of oxidative stress (DNP immunoreactivity,
SOD2, glutathione levels) and measures of neuropathy
(NCV and mechanical allodynia) were evaluated using
Spearman correlation statistics.
Results
Blood parameters in nondiabetic and
diabetic animals with and without LY379268
treatment
At the termination of the STZ diabetes experiment,
plasma glucose, glycosylated hemoglobin (GHb), insulin,
and lipid values were measured (Table 1). The mean
plasma glucose, glycosylated hemoglobin, and lipid profile
were significantly increased and insulin level significantly
decreased in diabetic compared to non-diabetic control
animals. The plasma glucose and glycosylated hemoglobin
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were not significantly altered with LY379268 treatment.
However, in diabetic rats treated with a high dose of
10 mg/kg/day LY379268, lipid measurements were
decreased compared to nontreated diabetic rats. Although
total cholesterol and HDL decreased, the most significant
relative decrease was in triglycerides [diabetic:
636  74.3 mg/dL versus Diabetic + LY (10):
311  52.4 mg/dL (P < 0.05)]. LY379268 treated diabetic
rats still had significantly higher lipid levels than nondia-
betic animals. We did not observe overt changes in
behavior and visual appearance in rats treated with
LY379268 up to 10 mg/kg/day.
Aged LCR rats were significantly more obese than HCR
rats.12 LCR rats had impaired glucose tolerance (IGT),
higher fasting blood glucose levels, increased cholesterol
and LDL levels compared to HCR rats (Figure S1,
Table 2). Treatment with LY379268 (10 mg/kg) improved
the metabolic profile of LCR rats. Rats showed decreased
body weight, increased insulin levels and decreased levels
of triglycerides and LDL (Table 2).
Nerve conduction, sensory testing, and
intraepidermal nerve fiber density
measurements to evaluate neuropathy in
diabetic rats with and without LY379268
treatment
The following studies determined the effect of the
mGluR2/3 agonist on neuropathy. After 8 weeks of dia-
betes, STZ treated rats showed a significant slowing of tail
motor and sensory and sciatic nerve (SN) motor nerve
conduction velocities (NCVs) compared with nondiabetic
control rats (Table 1) consistent with the development of
diabetic peripheral neuropathy DPN. In contrast, the dia-
betic animals treated with LY 379268 (3 & 10 mg/kg/day)
had preserved NCVs and the velocities were comparable
to nondiabetic rats consistent with protection against
DPN by an mGluR2/3 agonist. LY 379268 (10 mg/kg/
day) more effectively prevented neuropathy than 3 mg/
kg/day and was used in subsequent studies. In the case of
LCR rats, treatment with LY379268 for 8 weeks improved
the metabolic profile and nerve conduction velocities
(Table 2).
After 4 weeks of STZ-induced diabetes, there was a sig-
nificant decrease in withdrawal threshold as compared to
control rats (Fig. 1A; P < 0.001) that remained the same to
8 weeks, consistent with tactile allodynia. Diabetic animals
treated with LY 379268 (3 & 10 mg/kg) had significantly
reduced tactile allodynia (P < 0.001) at both 4 and 8 weeks
after initiation of treatment. With high dose LY379268
(10 mg/kg/day), the diabetic rats showed an increased
threshold to mechanical allodynia possibly due to the iden-
tified analgesic effect of LY379268 on nociception via TRP
channels in the hind paw.35 LCR rats showed evidence of
mechanical allodynia at the start of the study (prior to giv-
ing LY 379268) consistent with the presence of neuropathy
(Fig. 1B). When they were treated with high dose
LY379268 (10 mg/kg/day), their tactile allodynia threshold
improved to almost the level of HCR rats.
Examination of nerve fibers in skin biopsies from STZ-
induced diabetic rats showed a significant decrease in the
IENFD (Table 1 and Fig. 2A) compared to nondiabetic
rats. Intra-epidermal fiber density was lower in diabetic
than in control rats (9  0.6/mm vs.17  0.6/mm;
P < 0.001). The IENFD was 15.8  0.7/mm in treated
animals (P < 0.01 compared to diabetic).
Table 1. Metabolic and neuropathy end-points in nondiabetic, diabetic and LY379268-treated diabetic rats at 2 months
Parameters Control Diabetic Diabetic +LY (3) Diabetic +LY (10) Control +LY (3)
Body weight (g) 534  9.7 396  29.2*** 366  16.8*** 352  14.4*** 504  10.5
Plasma glucose (mg/dL) 88  4 535  22*** 495  11.4*** 544  23.2*** 80  2.4
% GHb 9.8  0.25 14  0 .35*** 14  0.82*** 14.1  0.6*** 8.8  0.74
Insulin (lU/mL) 8  1.45 2  0.02** 2  0.14** 2  0.29** 7  1.28
Total cholesterol (mg/dL) 64  4.39 166  27.5** 162  24.7** 120  14.6** 72  2.7
Triglycerides(mg/dL) 71  15 636  74*** 700  48*** 311  52.4+ 117  12.6
HDL (mg/dL) 23  1.25 43  2.43*** 28  3.39## 32  2.15## 25  0.87
LDL (mg/dL) 7  0.16 35  4.9*** 27  4.3*** 29  6.6*** 8  10.4
Tail MNV (m/s) 39  1 35  0.8* 39  0.5# 39  1# 37  1
Tail SNV (m/s) 55  2 44  1* 55  1# 61  2# 53  2
Sciatic MCV (m/s) 57  2 46  2*** 50  3 56  1### 54  3
IENFD (mm) 17  0.6 6  0.2*** 9  0.6# 15.8  0.7## 18  0.8
LDL, Low Density Lipoprotein; HDL, High Density Lipoprotein; MNV, Motor Nerve Conduction Velocity; SNV, Sensory Nerve Conduction Velocity;
IENFD, Intraepidermal Nerve Fiber Density.
*P < 0.05, **P < 0.01, & ***P < 0.001 diabetic compared to nondiabetic rats, +P < 0.05, #P < 0.05, ##P < 0.01 & ###P < 0.001 LY379268-trea-
ted diabetic as compared to untreated diabetic animals.
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In aged LCR rats there was a significant decrease in the
IENFD in LCR rat paw skin compared to HCR rats
(Table 2 and Fig. 2B) and treatment with LY379268
(10 mg/kg) for 2 months increased the IENFD from 9/
mm to 16/mm (P < 0.01). Thus, LY379268 prevented
neuropathy in an STZ model of T1DM experimental neu-
ropathy and treated neuropathy in a LCR IGT/hyperinsu-
linemic model.
Oxidative stress and oxidative stress
regulatory proteins (SIRT1, PGC1-a, and
TFAM) with and without LY379268
treatment
To study the mechanism of protection by LY379268 treat-
ment, we prepared DRG protein extracts and DNA from
non-diabetic, STZ diabetic and LY379268-treated diabetic
rats. The presence of protein carbonyls measured by 2, 4-
dinitrophenylhydrazine (DNPH) reactivity was used as a
marker of oxidative stress.36 Western blot revealed a sig-
nificantly increased DNP immunoreactivity in DRG from
diabetic rats as compared with nondiabetic animals
(Fig. 3A and B, ***P < 0. 001). Treatment with LY379268
(10 mg/kg) in diabetic animals significantly decreased
DNP to control levels (Fig. 3B ###P < 0.001). Western blot
analysis for the mitochondrial antioxidant protein SOD2
is shown in Figure 3C. SOD2 levels were not decreased in
diabetic animals, but the level was increased in LY379268
(10 mg/kg) treated DRG (Fig. 3C, ##P < 0.01) compared
to diabetic animals. The levels of SOD2 also increased in
LY379268 (3 mg/kg) treated control rats compared to
untreated control animals (#P < 0.05). Measurement of
total glutathione levels (Fig. 3D) showed a significant
decrease in diabetic DRG (***P < 0.001) and the levels
were normalized in LY379268 treated diabetic DRG. After
2 months of diabetes, DNP immunoreactivity and glu-
tathione levels significantly correlated with the sciatic-per-
oneal NCV and paw withdrawal thresholds (R2 = 0.64;
Table 2. Metabolic and neuropathy end-points in LCR, HCR and LY379268-treated LCR and HCR rats at 2 months.
Parameters LCR HCR LCR+LY (10) HCR+LY (10)
Body weight (g) 636  1.3*** 406  13 550  32# 387  29
Fasting glucose (mg/dL) 84  6.8*** 60  3 79  4 60  3
Insulin (ng/mL) 0.93  0.4** 0.62  0.19 0.71  0.1## 0.57  0.12
Total cholesterol (mg/dL) 143  8** 60  7 109  12 62  7
Triglycerides (mg/dL) 98  11 85  9 83  7# 83  6
HDL (mg/dL) 32.4  1.8 30.6  3.6 39.87  14.4 32  4.9
LDL (mg/dL) 104  29.4 29.34  1.6 84.19  3.8 28.33  3.2
Tail MNV (m/s) 34  1** 42  1 39  1# 40  1
Tail SNV (m/s) 44  3** 57  1 53  2# 58  2
Sciatic MNV (m/s) 49  2** 59  1 55  1# 59  1
IENFD (mm) 9  0.7*** 16.7  1 15.7  1## 17  1
LDL, Low Density Lipoprotein; HDL, High Density Lipoprotein; MNV, Motor Nerve Conduction Velocity; SNV, Sensory Nerve Conduction Velocity;
IENFD, Intraepidermal Nerve Fiber Density.
*P < 0.05, **P < 0.01 & ***P < 0.001 LCR compared to HCR; +P < 0.05, #P,0.05 & ##P < 0.01 LY379268-treated LCR as compared to untreated
LCR animals.
Figure 1. Von-Frey paw withdrawal threshold testing shows
improved mechanical allodynia in LY379268 treated STZ diabetic and
LCR rats. Mechanical allodynia (Von-Frey) testing was performed as
described in the Materials and Methods. Diabetic rats showed a
significant decrease in the paw withdrawal threshold. LY 379268
(10 mg/kg/day/i.p) treatment for 2 months significantly prevented
mechanical allodynia. The line represents the mean value and data for
individual animals are also given. Aged LCR rats showed increased
sensitivity to mechanical allodynia and LCR rats treated with
LY379268 at the high dose of 10 mg/kg/day improved their tactile
allodynia threshold to the level of HCR rats. ***P < 0.001 diabetic
compared to nondiabetic control rats and LCR compared to HCR;
###P < 0.001 in diabetic + LY 379268 (10 mg/kg) compared to
diabetic rats and LCR+LY379268 compared to LCR (10 mg/kg).
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P < 0.001), whereas the association was not significant
between SOD2 levels and NCV or paw withdrawal thresh-
olds (R2 = 0.06; NS).
The effect of diabetes and LY379268 treatment on key
mitochondrial transcription factors, for example SIRT1,
PGC-1a, TFAM (Fig. 4A) was determined using western
blotting in DRG from STZ diabetic rats (antibodies listed
in Table S1). SIRT1, PGC-1a and TFAM were all
increased in diabetic DRG (Fig. 4A to D; *P < 0.05) with
a further very significant increase in protein levels in
LY379268 treated DRG (Fig. 4A to D; ##P < 0.01) com-
pared to diabetic DRG. The ratio of mitochondrial
DNA (mtDNA) to nuclear DNA (nDNA) was determined
to measure the effect of diabetes and LY379168 treatment
on mtDNA (Table 3). The relative ratio of NADH dehy-
drogenase subunit 1 (ND1, encoded by mtDNA) over
beta-2-microglobulin (B2M, encoded by nDNA) showed
a significant decrease in diabetic DRG (**P < 0.01).
LY379268 (10 mg/kg) normalized mtDNA in diabetic
DRG. To determine changes in mitochondrial complex
levels, an OXPHOS antibody cocktail that detects sub-
units from 4 OXPHOS complexes was used (Fig. 5A;
quantification of the individual complexes is shown in
Figure 5B to D). The results showed a significant decrease
in the levels of subunits from OXPHOS complexes that
contain subunits encoded by mtDNA (Complex I, IV and
V). In contrast, Complex II, encoded entirely by nDNA,
showed no significant decrease.
Changes in glial fibrillary acidic protein
(GFAP), glutamine synthase (GS) and
glutamate transporters (GLT-1 and GLAST) in
diabetic DRG with and without LY379268
Treatment
LY379268 is a potent and selective agonist for the mGluR 2/
3 metabotropic glutamate receptor that has been shown in
the central nervous system to regulate glutamate metabolism
via glutamate recycling pathways that involve glial/neuronal
interactions and mitochondrial metabolism. We tested if
LY379268 also regulates glutamate recycling pathways in
DRG from STZ rats by measuring the protein levels of gluta-
mate transporter proteins [GLT-1 (EAAT2) and GLAST
(EAAT2)], GS and GFAP, a marker of gliosis (Fig. 6A). The
most significant result of this study was the dramatic
increase in GFAP in STZ diabetic DRG and return to basal
levels in LY379268 treated diabetic DRG similar to that in
nondiabetic DRG (Fig. 6B; P < 0.001). On the other hand,
Glutamine Synthetase (GS), a critical enzyme in the recy-
cling pathway of glutamate-glutamine cycle was decreased in
diabetic DRG and normalized in LY379268 treated DRG
(Fig. 6C; P < 0.001). A similar decrease was also noted in
GLT-1 and GLAST proteins in diabetic DRG and was nor-
malized in LY379268 treated diabetic DRG (Fig. 6D).
LCR DRG are positive for GFAP (Fig. 7A), whereas
HCR rats DRGs are mostly negative for GFAP. Treatment
of LCR rats with LY379268 decreased the levels of GFAP
(Fig. 7B, P < 0.001). We interpret this result to suggest
that a similar mechanism of activation of glutamate recy-
cling pathway occurs in LCR rats treated with LY379268,
to that observed in STZ diabetic rats.
Discussion
This the first in vivo study to confirm that the adminis-
tration of an mGluR3 agonist, LY379268, prevented neu-
ropathy in a STZ T1D model of diabetic neuropathy or
treated a LCR model of insulin resistance and glucose
intolerance with neuropathy. LY379268 [(-)-2-oxa-4-
Figure 2. Intraepidermal nerve fiber immunohistochemistry and fiber
counts in paw skin biopsy are improved in LY379268 treated STZ
diabetic and LCR rats. Images show 50 lm paw skin sections
immune-stained with anti-PGP 9.5 antibody. Small arrows indicate
intra-epidermal nerve fibers; large arrows indicate dermal nerve fibers
(scale bar 30 lm). There is a reduction in IENFD in STZ diabetic rats as
compared with nondiabetic animals (A). Treatment with 10 mg/kg
LY379268 in diabetic animals prevented the loss of epidermal fibers.
Similar improvement in IENFD was seen in LCR rats treated with
LY379268 (B).
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aminobicyclo(3.1.0)hexane-4,6-dicarboxylic acid] is a
highly potent and systemically available mGlu2/3 receptor
agonist.37,38 We propose a novel mechanism of protection
that involves activation of glutamate recycling pathways
to normalize mitochondrial OXPHOS metabolism.
Decreased sensitivity to pain with LY379268 treatment
has been noted following the injection of the inflammatory
agent carrageenan into the footpad of mice or with the
TRPV1 activator capsaicin.37 A similar analgesic effect is
also observed with (2R, 4R)-4-aminopyrrolidin-2, 4-
dicarboxylate, another Group II mGluR3 agonist.35 It was
supposed that these mGluR2/3 agonists modulate the sen-
sory receptors in the peripheral tissue and produce the
analgesic effect.35 The results presented here suggest that
activation of the group II mGlu2/3 receptor also occurs at
the level of DRG. LY379268 prevented diabetes-induced
nerve conduction slowing in both motor and sensory
axons, prevented somatosensory deficits as measured by
mechanical allodynia in distal nerve fibers in the hindlimb
and prevented diabetes-induced reduction in the most
Figure 3. The mGluR2/3agonist, LY379268, reduces oxidized proteins, and increases SOD2 and glutathione levels in diabetic DRG. Proteins were
extracted from DRG, run on 4 to12% SDS-PAGE, transferred to PVDF membrane and probed either with anti-DNP or with anti-SOD2 antibody.
The immunoreactivity was quantified using Image J software. For glutathione enzymatic measurement, nonprotein supernatant was used.
Oxidized protein measured by DNP was increased in diabetic DRG and reduced by LY379268 treatment (Figure A and B). LY379268 increased
SOD2 protein levels (Figure 3C) and normalized glutathione levels (Figure 3D). Figure 3B, ***P < 0.001 diabetic compared to nondiabetic control
rats; ###P < 0.001 diabetic + LY 379268 (10 mg/kg) compared to diabetic rats. In Figure 3C, #P < 0.05 and ##P < 0.01 LY 379268 treated
nondiabetic as compared control or diabetic rat. In Figure 3D,*** P < 0.001 diabetic compared to nondiabetic control rats.
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distal unmyelinated nerve fibers in the hindlimb paw epi-
dermis and dermis (Fig. 2).
In diabetic neuropathy, release of glutamate is associ-
ated with increased oxidative stress and decreased mito-
chondrial function.21,38 We interrogated this glutamate
hypothesis of DPN by inducing the glutamate reuptake
pathway with an mGluR2/3 agonist to elucidate the mech-
anism of protection. Glutamate is transported to the axon
terminals for synaptic release and induces an ionotropic
uptake mechanism involving Na+ and Ca2+ ions.39 Recent
evidence from the peripheral nervous system (PNS) show
that the machinery for production, paracrine release, and
recycling of glutamate occurs in sensory ganglia including
the enzymes amidohydrolase, glutaminase,40,41 GLAST,
GLT1,42 as well as the recycling enzyme GS.26,40 This local
release is a nonsynaptic glutamatergic transmission that
occurs within the ganglia. Nonsynaptic release of gluta-
mate into the extracellular space within the ganglion is
shown in cultured whole ganglia in response to KCl or
capsaicin.43 Knockdown of glutamate-glutamine recycle
enzymes or glutamate transporters result in increased
extracellular glutamate.44 The knockdown was found to be
confined to the satellite glial cells (SGC) that are found
wrapping the neuronal somata, isolating the ganglion cell
bodies.44,45 SGC contain all the protein necessary for the
uptake and recycling of glutamate.26 These findings
Figure 4. Western blot analysis of mitochondrial regulatory protein shows an increase in diabetic and a further increase in LY379268 treated STZ
diabetic DRG. The source and the dilution of the antibodies used are summarized in Table S1. (A–D) Western blots show that SIRT1, PGC-1a and
TFAM proteins were increased in diabetic DRG and treatment with LY379268 showed a further significant increase in SIRT1, PGC-1a and TFAM.
*P < 0.05 diabetic compared to nondiabetic rats; ##P < 0.01 diabetic + LY 379268 (10 mg/kg) compared to diabetic rats.
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suggest that glutamatergic transmission within the gan-
glion could impact the nociceptive threshold.46 Impor-
tantly DRG neurons do express glutamate receptors,
including mGluR2/3, in their soma. Thus, in addition to
the vesicular transport of glutamate to axon terminals for
synaptic release, the DRG neurons release and uptake






Control 10,600  1215 12,237 K  30 K 1145  175
Diabetic 11,350  1250 7160 K  69.7 K 630  75**
Diabetic + LY (3) 11,210  1250 9120 K  59.6K 807  75#
Diabetic + LY (10) 11,720  1200 13, 890 K  179 K 1170  190##
Control + LY (3) 11,920  1200 13, 930 K  161 K 1160  130
**P < 0.01 Diabetic versus Non-diabetic; #P < 0.05; ##P < 0.01; Diabetic + LY 379268 versus Diabetic.
Figure 5. mtDNA encoded OXPHOS complexes are reduced in diabetic DRG and normalized by LY379268. The source and the dilution of the
antibodies used are summarized in Table S1. Four monoclonal antibodies (mAbs), one each against OXOHOS complex (CI, CII, CIV and CV), CI
subunit NDUFB8, CII-30 kDa, CIV subunit I and CV alpha subunit as an optimized premixed cocktail. (A) Western blots of subunit proteins from 4
of the 5 OXPHOS complexes are shown. OXPHOS complexes I, III, IV and V contain subunits that are coded by mtDNA whereas OXPHOS complex
II contain subunits that are coded by nuclear DNA. Diabetic DRG showed a decrease in OXPHOS complexes that contain mtDNA-encoded
subunits (C-E) but not nDNA-encoded subunits (B). ***P < 0.001 diabetic compared to nondiabetic control rats; ##P < 0.01 diabetic + LY 379268
(10 mg/kg) compared to diabetic rats.
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glutamate for interganglionic glutamatergic communica-
tion.44, 45
Results from several investigators have shown GFAP to
be present at barely detectable levels in normal DRG. Dia-
betes markedly increases GFAP levels, suggesting that the
increase may represent induction of gliopathic pain.47
Treatment with the mGluR2/3 agonist, LY379268, pre-
vented increased GFAP levels. The increase in GFAP is
likely to represent differentiation of SGC as a response to
increased glutamate release in diabetes. The decrease in
levels of glutamate transporters and recycling proteins are
likely to exacerbate the glutamate accumulation and fur-
ther increase GFAP levels. All these changes are reversed
in rats treated with an mGluR2/3 agonist.
A mechanistic model (Fig. 8) is that hyperglycemia
induces oxidative stress, promotes release of glutamate
Figure 6. Western blot analysis of GFAP shows an increase in diabetic DRG whereas glutamate recycling enzymes (glutamine synthetase (GS),
glutamate transporters EAAT1 (GLAST) and EAAT2 (GLT-1) are decreased in diabetic DRG. LY369268 treatment reversed the increase in GFAP
and increased the glutamate recycling enzymes. The source and the dilution of the antibodies used are summarized in Table S1. (A) Western blots
show that GFAP was barely detectable in nondiabetic and LY379268 treated diabetic DRG extracts but showed a striking increase in diabetic DRG
extracts. GS, EAAT proteins decreased in diabetic DRG extracts but were normalized in LY379268 treated rat DRG extracts. (B) Quantification of
GFAP confirmed a 10-20-fold increase in GFAP levels in diabetic DRG compared to LY379268 treated diabetic and nondiabetic rat DRG. (C)
Glutamine synthetase and (D) Glutamate transporter protein levels were decreased in diabetic DRG extracts and were normalized with LY379268
treatment. ***P < 0.001 diabetic as compared with nondiabetic.
ª 2017. This article is a U.S. Government work and is in the public domain in the USA. Annals of Clinical and Translational Neurology
published by Wiley Periodicals, Inc. on behalf of American Neurological Association 853
K. Chandrasekaran et al. Glutamate Recycling and Diabetic Neuropathy
from DRG neurons, and that LY 379268 removes extra-
cellular glutamate by activating the glutamate recycling
pathway to decrease excitability of the neurons and pro-
mote neuroprotection.44,45,48 The mechanism that we pro-
pose is that LY379268 activates glutamate recycling
pathways in surrounding satellite glial cells (SGC), nor-
malizes neuronal mitochondrial OXPHOS metabolism
and prevents development of neuropathy. GFAP is one of
the markers that we used to advance this hypothesis of
increased glutamate recycling: diabetes increases GFAP-
positive SGC and LY379268 treatment decreased GFAP-
positive cells. This view is supported by the following evi-
dence: (1) There are three known glutamate transporter
proteins: GLAST, GLT1, and EAAC1.42 SGC express
GLAST1 and GLT1, whereas EAAC1 is expressed in neu-
rons.42 (2) Sciatic nerve injury decreases expression of
Figure 7. Western blot analysis of GFAP shows an increase in LCR DRG compared to HCR DRG neurons. LY369268 treatment reversed the
increase in GFAP in LCR DRG neurons. (A) Western blots show that GFAP was barely detectable in HCR and LY379268 treated HCR DRG extracts
but showed a striking increase in LCR DRG extracts and was significantly decreased in LY379268 treated LCR rat DRG extracts. (B) Quantification
of GFAP confirmed a 5-10-fold decrease in GFAP levels in LY379268 treated LCR compared to LCR rat DRG (***P < 0.001).
Figure 8. Proposed hypothesis: the role of satellite ganglion cells (SGC) and dorsal root ganglia (DRG) neurons in glutamate recycling. Glutamate
transporters GLT-1 and GLAST are present in SGC to transport extracellular glutamate into the SGC where glutamine synthetase (GS) converts it
to glutamine, which is eventually recycled to the neuron for conversion into glutamate. In diabetes, hyperglycemia-induced oxidative stress affects
glutamate transport proteins, increasing extracellular glutamate, causing expansion of GFAP positive SGC. LY379268 treatment promotes
glutamate uptake and is therefore likely to decrease extracellular glutamate, preventing expansion of GFAP positive SGC cells. In addition, mGluR
2/3 receptors present in DRG neurons decrease extracellular glutamate. Thus, activation of the mGluR2/3 receptor with an agonist likely
constrains sensory transmission and importantly nociceptive transmission. This allows modification of glutamate-induced receptor potentials before
impulses are generated and transmitted to the spinal cord.
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GLAST and GLT-1.49 This decrease in glutamate trans-
port causes an increase in extracellular glutamate, which
in turn is associated with neuropathic pain.49 (3) Rapid
removal of glutamate from the perineuronal space pre-
vents the cytotoxic effects of glutamate.39 (4) SGC cells
convert glutamate to glutamine using the enzyme GS and
glutamine is the taken up by neurons through glutamine
transporters and converted back to glutamate to be
reused. (5) mGluR2/3 receptors, present in DRG neurons,
can further reduce the levels of extracellular glutamate.
(6) Both neurons and SGC can eliminate the toxicity of
extracellular glutamate. (7) The synthesis of GSH involves
2 steps, ligation of glutamate with cysteine to form
gamma-glutamyl-cysteine and the addition of glycine to
the c-terminus to form GSH. This pathway exists in both
neurons and SGC. GSH made by SGC is secreted to the
intracellular space and taken up by neurons to replenish
GSH.50 This is consistent with our previous findings that
exposure to a mGluR2/3 agonist prevents glucose-induced
neuronal injury in DRG neuronal cultures, only in the
presence of Schwann/SGC cells, by increasing glutathione
and maintaining mitochondrial function.21,22,51 NMDA
receptor antagonists are not as protective as mGluR2/3
agonists suggesting that ionotropic pathways are not
involved in this pathway.21,22,51
Our results from western blots of mitochondrial tran-
scription factors and OXPHOS proteins suggest that the
physiological response to diabetic injury is insufficient to
protect DRG neurons. Levels of SIRT1, PGC-1a, and
TFAM were increased in STZ diabetic DRG after fairly
acute STZ-induced diabetes. In contrast, levels of PGC-1a,
and TFAM were decreased in more chronic diabetes.4 This
suggests that the mitochondrial machinery responds to
hyperglycemia-induced injury to DRG, albeit the response
is insufficient to protect them. LCR animals treated with
LY379269, there was a slight loss of weight and improve-
ment in LDL, triglyceride, and HDL levels. This may rep-
resent improved mitochondrial fatty acid metabolism
possibly related to upregulation of the SIRT1-PGC-1a-
TFAM axis (Fig. 4) but this will require further study.
Impaired lipid metabolism and accumulation of oxidized
lipids has clearly been implicated in the etiology of diabetic
neuropathy.52,53 In this study, HDL was increased in the
more acute STZ model of diabetes (Table 1) but reduced in
the more chronic LCR obesity model (Table 2). This is
similar to humans, where HDL levels are relatively pre-
served in young T1DM and reduced in chronic T2DM.54
PGC-1a is increased by treatment with LY379269 (Fig. 4)
and is implicated in improved mitochondrial fatty acid
metabolism13 and in the severity of diabetic neuropathy.4
Thus, potentially LY379269 may treat diabetic neuropathy
by reducing levels of certain toxic lipids and upregulating
proteins associated with improving mitochondrial
function. Recycling of glutamate with LY379268 further
increased levels of SIRT1, PGC-1a, and TFAM. This further
increase occurred even though LY379268 diabetic rats were
hyperglycemic (Table 1). TFAM regulates mitochondrial
replication and transcription.8 Even though levels of TFAM
were observed to be increased, our results showed a signifi-
cant decrease in overall DRG mtDNA levels (Table 3). One
plausible explanation for the paradox of increased TFAM
but decreased mtDNA is that although there is a physiolog-
ical upregulation of TFAM due to hyperglycemia, there is
also an increase in protein oxidation (Fig. 3). The result is
that even though TFAM protein levels increased, TFAM
was ubiquitinated causing it to be nonfunctional and thus
preventing TFAM-induced mtDNA replication and tran-
scription.55
Overall the present study indicates that a selective
mGluR2/3 agonist is effective in reducing the severity of
diabetic neuropathy. Our results provide in vivo evi-
dence supporting the previous in vitro data obtained
from DRG neuronal and Schwann cell cultures.21,22,51 In
vitro results delineated a potential mechanism of reduc-
ing oxidative stress by increasing glutathione levels that
did not involve ionotropic NMDA pathways but likely
involved metabolomic mGluR pathways. Our hypothesis
summarized in Figure 8 suggests that one mechanism of
protection is likely to involve presynaptic glutamate
release, glutamate uptake, conversion of glutamate to
glutamine to provide precursors for GSH synthesis, and
substrate for neuronal mitochondrial oxidative metabo-
lism. In turn, improved Mt function with LY379269 is
associated with upregulation of the SIRT1-PGC-1a-
TFAM axis.
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Figure S1. Intraperitoneal Glucose Tolerance Test shows
impaired glucose tolerance in LCR rats compared to HCR
rats. Mean blood glucose after administration of
intraperitoneal glucose challenge (1.5 g/kg/) in HCR and
LCR rats. Data is in mean  SEM. *P<0.05; **P<0.01
LCR compared to HCR rats.
Table S1. Source and the dilutions of the antibodies used
in this study.
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